0001493152-24-007487.txt : 20240221
0001493152-24-007487.hdr.sgml : 20240221
20240221213815
ACCESSION NUMBER: 0001493152-24-007487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kilcoyne Adrian
CENTRAL INDEX KEY: 0001857963
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38914
FILM NUMBER: 24662064
MAIL ADDRESS:
STREET 1: 533 AIRPORT BLVD.
STREET 2: SUITE 400
CITY: BURLINGAME
STATE: CA
ZIP: 94010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celularity Inc
CENTRAL INDEX KEY: 0001752828
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831702591
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (908) 768-2170
MAIL ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
FORMER COMPANY:
FORMER CONFORMED NAME: GX Acquisition Corp.
DATE OF NAME CHANGE: 20180912
4
1
ownership.xml
X0508
4
2024-02-16
0
0001752828
Celularity Inc
CELU
0001857963
Kilcoyne Adrian
C/O CELULARITY INC.
170 PARK AVENUE
FLORHAM PARK
NJ
07932
0
1
0
0
Chief Medical Officer
0
Class A Common Stock
2024-02-17
4
F
0
52762
0.434
D
1122238
D
Stock Option Grant (Right to Buy)
0.4340
2024-02-16
4
A
0
205213
0.00
A
2034-02-15
Class A Common Stock
205213
205213
D
Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.
Reflects shares underlying RSUs subject to vesting.
The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date.
/s/ Kyle Fletcher, Attorney-in-Fact
2024-02-21